

Andrew C Edmondson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7330445/publications.pdf>

Version: 2024-02-01

30
papers

800
citations

623734

14
h-index

526287

27
g-index

33
all docs

33
docs citations

33
times ranked

1529
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline gain-of-function mutations in <i>AFF4</i> cause a developmental syndrome functionally linking the super elongation complex and cohesin. <i>Nature Genetics</i> , 2015, 47, 338-344.	21.4	109
2	Loss of Function of <i>GALNT2</i> Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents. <i>Cell Metabolism</i> , 2016, 24, 234-245.	16.2	103
3	The Metabolic Map into the Pathomechanism and Treatment of <i>PGM1</i> -CDG. <i>American Journal of Human Genetics</i> , 2019, 104, 835-846.	6.2	59
4	Overgrowth Syndromes. <i>Journal of Pediatric Genetics</i> , 2015, 04, 136-143.	0.7	57
5	Gain-of-function mutations in <i>SMAD4</i> cause a distinctive repertoire of cardiovascular phenotypes in patients with Myhre syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 2617-2631.	1.2	53
6	Novel congenital disorder of <i>O</i> -linked glycosylation caused by <i>GALNT2</i> loss of function. <i>Brain</i> , 2020, 143, 1114-1126.	7.6	46
7	Clinical and biochemical improvement with galactose supplementation in <i>SLC35A2</i> -CDG. <i>Genetics in Medicine</i> , 2020, 22, 1102-1107.	2.4	42
8	Increased Clinical Sensitivity and Specificity of Plasma Protein N-Glycan Profiling for Diagnosing Congenital Disorders of Glycosylation by Use of Flow Injection- <i>Electrospray Ionization</i> - <i>Quadrupole Time-of-Flight Mass Spectrometry</i> . <i>Clinical Chemistry</i> , 2019, 65, 653-663.	3.2	40
9	Congenital hyperinsulinism as the presenting feature of Kabuki syndrome: clinical and molecular characterization of 10 affected individuals. <i>Genetics in Medicine</i> , 2019, 21, 233-242.	2.4	39
10	International consensus guidelines for phosphoglucomutase 1 deficiency (<i>PGM1</i> -CDG): Diagnosis, follow-up, and management. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 148-163.	3.6	27
11	<i>ECHS1</i> Deficiency as a Cause of Severe Neonatal Lactic Acidosis. <i>JIMD Reports</i> , 2016, 30, 33-37.	1.5	26
12	Sorbitol Is a Severity Biomarker for <i>PMM2</i> -CDG with Therapeutic Implications. <i>Annals of Neurology</i> , 2021, 90, 887-900.	5.3	22
13	X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of <i>CDKL5</i> deficiency disorder. <i>Neurobiology of Disease</i> , 2021, 148, 105176.	4.4	21
14	A human case of <i>SLC35A3</i> -related skeletal dysplasia. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 2758-2762.	1.2	20
15	Missed Newborn Screening Case of Carnitine Palmitoyltransferase-II Deficiency. <i>JIMD Reports</i> , 2016, 33, 93-97.	1.5	17
16	Early infantile epileptic encephalopathy due to biallelic pathogenic variants in <i>PIGQ</i> : Report of seven new subjects and review of the literature. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1321-1332.	3.6	15
17	Liver manifestations in a cohort of 39 patients with congenital disorders of glycosylation: pin-pointing the characteristics of liver injury and proposing recommendations for follow-up. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 20.	2.7	14
18	Kabuki syndrome as a cause of non-immune fetal hydrops/ascites. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 3333-3337.	1.2	11

#	ARTICLE	IF	CITATIONS
19	Newborn Screening for X-Linked Adrenoleukodystrophy: Review of Data and Outcomes in Pennsylvania. <i>International Journal of Neonatal Screening</i> , 2022, 8, 24.	3.2	11
20	Patient-reported outcomes and quality of life in PMM2-CDG. <i>Molecular Genetics and Metabolism</i> , 2022, 136, 145-151.	1.1	10
21	<i>ALG13</i> X-linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypes. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1001-1012.	3.6	9
22	Bi-allelic variants in the ER quality-control mannosidase gene EDEM3 cause a congenital disorder of glycosylation. <i>American Journal of Human Genetics</i> , 2021, 108, 1342-1349.	6.2	9
23	Spontaneous improvement of carbohydrate-deficient transferrin in PMM2-CDG without mannose observed in CDG natural history study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 102.	2.7	8
24	PIGG variant pathogenicity assessment reveals characteristic features within 19 families. <i>Genetics in Medicine</i> , 2021, 23, 1873-1881.	2.4	5
25	Expanding the phenotypic spectrum of ARCN1-related syndrome. <i>Genetics in Medicine</i> , 2022, 24, 1227-1237.	2.4	5
26	<i>ALG8</i> CDG: Molecular and phenotypic expansion suggests clinical management guidelines. <i>Journal of Inherited Metabolic Disease</i> , 2022, 45, 969-980.	3.6	5
27	Expanding the phenotype, genotype and biochemical knowledge of <i>ALG3</i> CDG. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 987-1000.	3.6	4
28	Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?. <i>Molecular Genetics and Metabolism</i> , 2021, 133, 397-399.	1.1	3
29	A rare cause of infantile achalasia: <i>GMPPA</i> congenital disorder of glycosylation with two novel compound heterozygous variants. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 2438-2442.	1.2	3
30	Manifestations and Management of Hepatic Dysfunction in Congenital Disorders of Glycosylation. <i>Clinical Liver Disease</i> , 2021, 18, 54-66.	2.1	0